Prevalence of the 23 S rRNA A 2058 G Point Mutation and Molecular Subtypes in Treponema pallidum in the United States , 2007 to 2009 The A 2058

Background: The 23S rRNA A2058G point mutation in Treponema pallidum is associated with macrolide antibiotic treatment failure. Its prevalence and potential association with a molecular subtype within the United States are unknown. Methods: During 2007 to 2009, 11 clinics across the United States sent samples from genital ulcers to the Centers for Disease Control and Prevention. Molecular techniques were used to identify T. pallidum DNA sequences, the A2058G mutation, and subtype of T. pallidum. Accompanying epidemiologic information was abstracted from medical records. Results: A total of 141 samples with T. pallidum were collected from individuals whose median age was 33 years (range, 13Y68 years): 118 were male (69% reported as men having sex with men [MSM]). The A2058G mutation was carried in 75 samples (53%) with T. pallidum, with samples from MSM (versus women and other men) more likely carrying the A2058G mutation (65/82 samples versus 8/57 samples; prevalence ratio, 5.7; 95% confidence interval, 2.9Y10.8). Of 98 strain-typed samples, 61 (62%) were the 14d9 subtype of T. pallidum, which was also associated with samples with T. pallidum from MSM (prevalence ratio, 3.5; 95% confidence interval, 1.9Y6.5). However, among T. pallidum from MSM, the A2058G mutation was not associated with the 14d9 subtype. Conclusions: The A2058G mutation and 14d9 subtype of T. pallidum were present throughout the United States. Both were more commonly found in T. pallidum from MSM compared with women or other men but were not associated with each other. Treating syphilis with azithromycin should be done cautiously and only when treatment with penicillin or doxycycline is not feasible.

[1]  J. Fyfe,et al.  Molecular Subtyping of Treponema pallidum during a Local Syphilis Epidemic in Men Who Have Sex with Men in Melbourne, Australia , 2012, Journal of Clinical Microbiology.

[2]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[3]  P. Zhou,et al.  Azithromycin Treatment Failure Among Primary and Secondary Syphilis Patients in Shanghai , 2010, Sexually transmitted diseases.

[4]  M. Golden,et al.  Enhanced molecular typing of treponema pallidum: geographical distribution of strain types and association with neurosyphilis. , 2010, The Journal of infectious diseases.

[5]  H. Zhu,et al.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage , 2010, Andrologia.

[6]  S. Chisholm,et al.  High-Level Azithromycin Resistance Occurs in Neisseria gonorrhoeae as a Result of a Single Point Mutation in the 23S rRNA Genes , 2010, Antimicrobial Agents and Chemotherapy.

[7]  F. Behets,et al.  A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. , 2010, The Journal of infectious diseases.

[8]  I. Martin,et al.  Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  L. Wallace,et al.  Molecular epidemiology of syphilis in Scotland , 2009, Sexually Transmitted Infections.

[10]  G. Weinstock,et al.  Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidum. , 2009, Journal of medical microbiology.

[11]  I. Martin,et al.  Molecular Characterization of Syphilis in Patients in Canada: Azithromycin Resistance and Detection of Treponema pallidum DNA in Whole-Blood Samples versus Ulcerative Swabs , 2009, Journal of Clinical Microbiology.

[12]  J. P. Gomes,et al.  Molecular Typing of Treponema pallidum Clinical Strains from Lisbon, Portugal , 2008, Journal of Clinical Microbiology.

[13]  D. Palmero,et al.  Mycobacterium avium complex infection in HIV/AIDS patients , 2008, Expert review of anti-infective therapy.

[14]  M. Siedner,et al.  Detection of Azithromycin Resistance in Treponema pallidum by Real-Time PCR , 2007, Antimicrobial Agents and Chemotherapy.

[15]  S. Berman,et al.  Trends in primary and secondary syphilis among men who have sex with men in the United States. , 2007, American journal of public health.

[16]  C. Marra,et al.  Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. , 2006, The Journal of infectious diseases.

[17]  D. L. Cox,et al.  Diagnosis of Gastric Syphilis by Direct Immunofluorescence Staining and Real-Time PCR Testing , 2006, Journal of Clinical Microbiology.

[18]  C. Kent,et al.  Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Morshed,et al.  Determining optimal catheterization rates , 2006, Canadian Medical Association Journal.

[20]  S. Groseclose,et al.  The Changing Epidemiology of Syphilis , 2005, Sexually transmitted diseases.

[21]  M. Hoelscher,et al.  Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. , 2005, The New England journal of medicine.

[22]  A. Seña,et al.  Molecular Subtyping of Treponema pallidum from North and South Carolina , 2005, Journal of Clinical Microbiology.

[23]  H. Ohya,et al.  Characterization and Molecular Analysis of Macrolide-Resistant Mycoplasma pneumoniae Clinical Isolates Obtained in Japan , 2004, Antimicrobial Agents and Chemotherapy.

[24]  J. Klausner,et al.  Macrolide resistance in Treponema pallidum in the United States and Ireland. , 2004, The New England journal of medicine.

[25]  L. Finelli,et al.  Molecular subtyping of Treponema pallidum in an Arizona County with increasing syphilis morbidity: use of specimens from ulcers and blood. , 2001, The Journal of infectious diseases.

[26]  M. Morshed,et al.  Mass treatment/prophylaxis during an outbreak of infectious syphilis in Vancouver, British Columbia. , 2000, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[27]  L. Stamm,et al.  A Point Mutation Associated with Bacterial Macrolide Resistance Is Present in Both 23S rRNA Genes of an Erythromycin-ResistantTreponema pallidum Clinical Isolate , 2000, Antimicrobial Agents and Chemotherapy.

[28]  E. Hook,et al.  Azithromycin Compared with Penicillin G Benzathine for Treatment of Incubating Syphilis , 1999, Annals of Internal Medicine.

[29]  S. Morse,et al.  Molecular Subtyping of Treponema pallidum Subspecies pallidum , 1998, Sexually transmitted diseases.

[30]  J. Stapleton,et al.  In vitro assay to demonstrate high-level erythromycin resistance of a clinical isolate of Treponema pallidum , 1988, Antimicrobial Agents and Chemotherapy.